计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
,适用于对基线干扰要求严格的色谱和分析工作流程。
充氩,-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
SRPKIN-1 is a covalent and irreversible SRPK1/2 inhibitor with IC 50 s of 35.6 and 98 nM, respectively. Anti-angiogenesis effect
In Vitro
SRPKIN-1 treatment at 200 nM (10, 50, 100, 200 nM, 16 hours) significantly reduces SR protein phosphorylation at the steady state with or without washout. ? SRPK-IN-1 potently converts VEGF from pro-angiogenic to anti-angiogenic isoform. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Ba/F3 cells Concentration: 0-10000 nM Incubation Time: 72 h Result: Potently decreased the level of SR phosphorylation in a dose-dependent manner, leading to increased VEGF-A165b RNA as well as protein even at a dose of 200 nM.
In Vivo
SRPKIN-1 (50 nM, 300 nM,1 μL, 5 times) blocks angiogenesis in a CNV mouse model through VEGF alternative splicing . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice Dosage: 50 nM, 300 nM, 1 μL Administration: Intravitreal injection, 5 times Result: SRPKIN-1-treated mice is significantly suppressed in a dose-dependent manner based upon measurement of the CNV area .
IC50& Target:IC50: 35.6 nM (SRPK1), 98 nM (SRPK2)